PLK1 and acute lymphoblastic leukemia: The findings indicate that venetoclax-resistant T-ALL demonstrates PLK1 pathway enrichment and sensitivity to PLK1 inhibition, while venetoclax treatment promotes PLK1 phosphorylation.